Mylan Has Green Light On Remdesivir
Follows Cipla And Hetero Launches Of COVID-19 Treatment
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
